Quantcast

Latest Eisai Stories

2014-05-15 08:29:02

Obesity Education Network Provides Tools to Help Physicians Assess and Manage Patients Who are Overweight or Obese WOODCLIFF LAKE, N.J., May 15, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of a website that will provide physicians with access to comprehensive clinical information that addresses obesity screening and risk assessment, provider-patient partnerships and weight loss management. The website, called the Obesity Education Network (OEN), www.obesityeducationnetwork.com,...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-12 16:28:57

-- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time -- SAN DIEGO, May 12, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2014. "We are off to a productive start in 2014 with significant new marketing initiatives for BELVIQ® for chronic weight management, the advancement of our lorcaserin life-cycle management programs and the development of our...

2014-05-09 08:26:05

-- Expansion to Approximately 600 Sales Specialists Follows Initiation of National Television Advertising Campaign -- SAN DIEGO, May 9, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales...

2014-05-09 08:25:56

Expansion Enables Eisai to Reach 90,000 Healthcare Providers WOODCLIFF LAKE, N.J., May 9, 2014 /PRNewswire/ -- Eisai Inc. announced today it will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ(®) to approximately 600, triple the size from when the FDA-approved prescription therapy for chronic weight management became available in June 2013. This expansion, which becomes effective on July 1, 2014, will allow Eisai...

2014-04-29 08:34:54

-- Doctors Can Help Patients Set Personal Weight Loss Goals: It's Not a One Size Fits All Approach -- WOODCLIFF LAKE, N.J., April 29, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of My Healthy(TM), an interactive and motivational campaign that shifts the focus of the obesity conversation away from just pounds lost to health gained. Almost 70 percent of Americans are affected by obesity or overweight. This movement emphasizes that those affected by obesity or overweight...

2014-04-24 08:33:54

Patent covers methods of use for small molecule inhibitors in the treatment of NHL, including follicular and diffuse large B-cell lymphomas CAMBRIDGE, Mass., April 24, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application...

2014-04-14 12:27:47

Campaign Creates Awareness of Prescription Drug Option for Chronic Weight Management WOODCLIFF LAKE, N.J., April 14, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ(®) (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC. To view the multimedia assets associated with this release, please click:...

2014-04-08 08:30:17

Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients...

2014-03-31 04:20:57

WOODCLIFF LAKE, N.J., March 31, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN(®) (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. Eisai will retain its rights for DACOGEN(®) in Mexico. In...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.